Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239943 | 0.81 | — | — | |
| SCHEMBL3688793 | 0.77 | — | — | |
| SCHEMBL3069942 | 0.69 | — | — | |
| SCHEMBL15062465 | 0.68 | CA1 (0.36) | CA1CA9 | |
| SCHEMBL277103 | 0.68 | CA1 (0.32) | CA1CA9CYP2B6 | |
| SCHEMBL2122929 | 0.67 | CA1 (0.31) | CA1CA9 | |
| SCHEMBL9208 | 0.66 | CYP2B6 (0.43) | CA1CA9CYP2B6ABCG2ITGB2 | |
| SCHEMBL2281562 | 0.66 | CYP2B6 (0.43) | CA1CA9CYP2B6ABCG2ITGB2 | |
| SCHEMBL2289180 | 0.66 | CYP2B6 (0.43) | CA1CA9CYP2B6ABCG2ITGB2 | |
| SCHEMBL29364609 | 0.66 | CYP2B6 (0.43) | CA1CA9CYP2B6ABCG2ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | claimed |
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | claimed |
| EP-0188502-A1 | ETHERIFIED 2-HYDROXY-ETHYL-PHOSPHONIC ACID DERIVATIVES AND PLANT GROWTH REGULATING AGENTS CONTAINING SAME AS ACTIVE INGREDIENT. | NITROKEMIA IPARTELEPEK (HU) | 1986-07-30 | — | — | EP | claimed |
| WO-1986000904-A1 | ETHERIFIED 2-HYDROXY-ETHYL-PHOSPHONIC ACID DERIVATIVES AND PLANT GROWTH REGULATING AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | NITROKÉMIA IPARTELEPEK (HU) | 1986-02-13 | — | — | WO | claimed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-20180201989-A1 | OXIDANT AND USE THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9751821-B1 | Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-5840909-A | Pyrazole derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5817828-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| US-5721264-A | EXHIBIT ANTAGONISTIC EFFECT AGAINST ANGIOTENSIN II; USEFUL FOR PREVENTION AND REMEDY OF HYPERTENSION, CONGESTIVE HEARTFAILURE, CHRONIC RENAL INSUFFICIENCY, ALDOSTERONISM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0811629-A1 | OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-12-10 | — | — | EP | disclosed |
| EP-0693480-A1 | PYRAZOLE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
| CN-88101155-A | The preparation of benzo benzodioxole derivatives and application thereof | — | 1988-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CA1 1625/4885CA9 1934/4885CYP2B6 1573/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | CA1 3993/4885CA9 3025/4885CYP2B6 2287/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | CA1 3993/4885CA9 3025/4885CYP2B6 2287/4885 |
| US-20170233321-A1 | METHOD FOR PRODUCTION OF 3-HYDROXYPROPAN-1-ONE COMPOUND, METHOD FOR PRODUCTION OF 2-PROPEN-1-ONE COMPOUND AND METHOD FOR PRODUCTION OF ISOXAZOLINE COMPOUND | ADH1C, ADH1A, CYP2E1 | CA1 343/4885CA9 2960/4885CYP2B6 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.